Skip to main content
SpringerLink
Log in
Book cover

Multidrug-resistant Tuberculosis pp 213–224Cite as

Chemoprophylaxis and BCG in contacts of multidrugresistant tuberculosis

  • Chapter

Part of the book series: Resurgent and Emerging Infectious Diseases ((REID,volume 1))

Abstract

The emerging threat of multi-drug resistant tuberculosis (MDRTB) has many adverse implications. Persons with active disease due to multidrugresistant Mycobacterium tuberculosis represent a major public health problem because they can transmit a disease that is potentially untreatable. The cost to the individual and the community is enormous considering the degree of individual suffering from being chronically diseased, having longterm complex and toxic therapy, prolonged hospitalisation, loss of social contact and possibly the means of livelihood. There is no clear consensus on the most effective regimens in treating those that have the disease and those that are infected. The cost of treatment is excessive and current therapeutic regimens have a high failure rate often resulting in death. The risk of infection to health care workers (HCW) is a major problem and ways to minimise these risks have to be actively pursued. There is the added dilemma of how best to protect the uninfected. There are no easy or certain solutions to these problems.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sepkowitz KA. How contagious is tuberculosis? Clin Infect Dis 1996; 23: 954–962.

    Article  PubMed  CAS  Google Scholar 

  2. Snider DE Jr, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985; 132: 125–132.

    PubMed  Google Scholar 

  3. Kritski AL, Marques MJO, Rabahi MF, Vieira MAMS, Werneck-Barroso E, Carvalho CES, Andrade GDN, Bravo-De-Souza R, Andrade LM, Gontijo PP, Riley LW. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153: 331–335.

    PubMed  CAS  Google Scholar 

  4. Jarvis W, Richards C. Administrative, engineering, and personal protective measures for controlling multidrug-resistant tuberculosis, Chapter 18, 269–284. In: Bastian I, Portaels F (eds.), Multidrug resistant tuberculosis. Kluwer Academic Publ, The Netherlands, 2000.

    Google Scholar 

  5. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1994; 43(RR-13): 1–132.

    Google Scholar 

  6. Institutional control measures for tuberculosis in the era of multiple drug resistance. ACCP/ATS Consensus Conference. Chest 1995; 108: 1690–1710.

    Article  Google Scholar 

  7. Blumberg HM, Watkins DL, Berschling JD, Antle A, Moore P, White N, Hunter M, Green B, Ray SM, McGowan Jr JE. Preventing nosocomial transmission of tuberculosis. Ann Intern Med 1995; 122: 658–663.

    PubMed  CAS  Google Scholar 

  8. Maloney SA, Pearson ML, Gordon MT, Del Castillo R, Boyle JF, Jarvis WR. Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers. Ann Intern Med 1995; 122: 90–95.

    PubMed  CAS  Google Scholar 

  9. Adal KA, Anglim AM, Palumbo CL, Titus MG, Coyner BJ, Farr BM. The use of highefficiency particulate air-filter respirators to protect hospital workers from tuberculosis: a cost-effectiveness analysis. N Engl J Med 1994; 331: 169–173.

    Article  PubMed  CAS  Google Scholar 

  10. Ferebee SH, Palmer CE. Prevention of experimental tuberculosis with isoniazid. Am Rev Tuberc Pul Dis 1956; 73: 1–18.

    CAS  Google Scholar 

  11. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979; 119: 827–830.

    PubMed  CAS  Google Scholar 

  12. Efficacy of various durations of isoniazid preventative therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60: 555–564.

    Google Scholar 

  13. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13: 501–507.

    Article  PubMed  CAS  Google Scholar 

  14. Bass JB Jr, Farer LS, Hopewell PC, O’Brien R, Jacobs RF, Ruben F, Snider DE Jr, Thornton G. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149: 1359–1374.

    PubMed  Google Scholar 

  15. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579–1583.

    Article  PubMed  Google Scholar 

  16. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989; 140: 1189–1193.

    Article  PubMed  CAS  Google Scholar 

  17. A double-blind placebo-controlled clinical trial of three anti-tuberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992; 145: 36–41.

    Article  Google Scholar 

  18. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O’Brien RJ, Olliaro P, Roscigno G, Grosset J. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148: 1541–1546.

    Article  PubMed  CAS  Google Scholar 

  19. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR Jr, Hopewell PC. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restrictionfragment-length polymorphisms. N Engl J Med 1992; 326: 231–235.

    Article  PubMed  CAS  Google Scholar 

  20. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis 1992; 73: 311–321.

    Article  PubMed  CAS  Google Scholar 

  21. Nakata K, Rom WN, Honda Y, Condos R, Kanegasaki S, Cao Y, Weiden M. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997; 155: 996–1003.

    PubMed  CAS  Google Scholar 

  22. Tuberculosis preventive therapy in HIV-infected individuals. A joint statement of the WHO Tuberculosis Programme and the global Programme on AIDS, and the International Union Against Tuberculosis and Lung Disease (IUATLD). Wkly Epidemiol Rec 1993; 68: 361–364.

    Google Scholar 

  23. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, Smith PJ, Carson ML, Geiter LJ. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155: 1735–1738.

    PubMed  CAS  Google Scholar 

  24. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O’Connell JJ, McInnis B, Nieves RL, Bernardo J. Rifampin preventive therapy for tuberculosis in Boston’s homeless. Am J Respir Crit Care Med 1996; 154: 1473–1477.

    PubMed  CAS  Google Scholar 

  25. Livengood JR, Sigler TG, Foster LR, Bobst JG, Snider DE Jr. Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. JAMA 1985; 253: 2847–2849.

    Article  PubMed  CAS  Google Scholar 

  26. Bishai WR, Graham NMH, Harrington S, Page C, Moore-Rice K, Hooper N, Chaisson RE. Brief Report: Rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med 1996; 334: 1573–1576.

    Article  PubMed  CAS  Google Scholar 

  27. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-11): 61-71.

    Google Scholar 

  28. Passannante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi survey. Chest 1994; 106: 431–434.

    Article  PubMed  CAS  Google Scholar 

  29. Stevens JP, Daniel TM. Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using Ciprofloxacin and pyrazinamide. A decision analysis. Chest 1995; 108: 712–717.

    Article  PubMed  CAS  Google Scholar 

  30. Heifets L, Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semi dormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 1992; 145: 1223–1225.

    Article  PubMed  CAS  Google Scholar 

  31. Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El-Sadr W, Blum S, Gagliardi A, Salomon N, Turett G. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907–911.

    Article  PubMed  CAS  Google Scholar 

  32. Sirgel FA, Botha FJ, Parkin DP, Van de Wal BW, Schall R, Donald PR and Mitchison DA. The early bactericidal activity of Ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 901–905.

    PubMed  CAS  Google Scholar 

  33. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219–225.

    Article  PubMed  CAS  Google Scholar 

  34. Menzies D, Adhikari N, Tannenbaum T. Patient characteristics associated with failure of tuberculosis prevention. Tuber Lung Dis 1996; 77: 308–314.

    Article  PubMed  CAS  Google Scholar 

  35. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1996; 45(RR-4): 1-18.

    Google Scholar 

  36. Brewer TF, Colditz GA. Bacille Calmette-Guérin vaccination for the prevention of tuberculosis in health care workers. Clin Infect Dis 1995; 20: 136–142.

    Article  PubMed  CAS  Google Scholar 

  37. Stevens JP, Daniel TM. Bacille Calmette Guérin immunization of health care workers exposed to multidrug-resistant tuberculosis: a decision analysis. Tuber Lung Dis 1996; 77: 315–321.

    Article  PubMed  CAS  Google Scholar 

  38. Marcus AM, Rose DN, Sacks HS, Schechter CB. BCG vaccination to prevent tuberculosis in health care workers: a decision analysis. Prev Med 1997; 26: 201–207.

    Article  PubMed  CAS  Google Scholar 

  39. Jenney AWJ, Spelman DW. In support of Bacillus of Calmette and Guérin for healthcare workers. Infect Control Hosp Epidemiol 1998; 19: 191–193.

    Article  PubMed  CAS  Google Scholar 

  40. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22: 1154–1158.

    Article  PubMed  CAS  Google Scholar 

  41. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698–702.

    Article  PubMed  CAS  Google Scholar 

  42. Greenberg PD, Lax KG, Schechter CB. Tuberculosis in house staff. A decision analysis comparing the tuberculin screening strategy with the BCG vaccination. Am Rev Respir Dis 1991; 143: 490–495.

    PubMed  CAS  Google Scholar 

  43. Reichman LB, Jordan TJ. Decision analysis comparing the tuberculin screening strategy with BCG vaccine. Am Rev Respir Dis (letter) 1992; 145: 732.

    CAS  Google Scholar 

  44. Nolan CM, Elarth AM, Barr H, Saeed AM, Risser DR. An outbreak of tuberculosis in a shelter for homeless men. A description of its evolution and control. Am Rev Respir Dis 1991; 143: 257–261.

    PubMed  CAS  Google Scholar 

  45. Nettleman M. Use of BCG vaccine in shelters for the homeless: A decision analysis. Chest 1993; 103: 1087–1090.

    Article  PubMed  CAS  Google Scholar 

  46. Lotte A, Wasz-Hockert O, Poisson N, Engbaek H, Landmann H, Quast U, Andrasofszky B, Lugosi L, Vadasz Mihailescu P, Pal D, Sudic D. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuber Lung Dis 1988; 63: 47–59.

    CAS  Google Scholar 

  47. Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. N Engl J Med 1995; 332: 92–98.

    Article  PubMed  CAS  Google Scholar 

  48. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: Review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997; 24(Suppl 1): S121–130.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. South Australian Tuberculosis Sevices, Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia

    Richard A. Stapledon

  2. Infectious Diseases Laboratories, Institute of Medical and Vetirinary Science, PO Box 14, Rundle Mall, Adelaide, SA, 5000, Australia

    Richard Lumb & Irene S. Lim

Authors
  1. Richard A. Stapledon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Lumb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irene S. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mycobacterium Reference Laboratory, Institute of Medical & Veterinary Science, Adelaide, Australia

    Ivan Bastian

  2. Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium

    Françoise Portaels

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Stapledon, R.A., Lumb, R., Lim, I.S. (2000). Chemoprophylaxis and BCG in contacts of multidrugresistant tuberculosis. In: Bastian, I., Portaels, F. (eds) Multidrug-resistant Tuberculosis. Resurgent and Emerging Infectious Diseases, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4084-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4084-3_14

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5794-3

  • Online ISBN: 978-94-011-4084-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation